Ending “Buy-And-Bill” in Oncology: The Question is How, Not If
This article was originally published in RPM Report
Executive Summary
The public policy debate over affordability of cancer care is approaching consensus on the need to end the “buy-and-bill” model for chemotherapy. How, and how fast, are the key remaining questions. For biopharma manufacturers, there are good reasons to embrace the change.